nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

04.06.2016 | Original Article

Amyloid- and FDG-PET imaging in amyotrophic lateral sclerosis

verfasst von: Jordi A. Matías-Guiu, Vanesa Pytel, María Nieves Cabrera-Martín, Lucía Galán, María Valles-Salgado, Antonio Guerrero, Teresa Moreno-Ramos, Jorge Matías-Guiu, José Luis Carreras

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 11/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We aimed to study brain metabolism and presence of beta-amyloid deposits using positron emission tomography (PET) in patients with amyotrophic lateral sclerosis (ALS).

Methods

This prospective cross-sectional study included 18 patients with definite or probable ALS according to the revised El Escorial diagnostic criteria, and 24 healthy controls. Patients underwent neurological and neuropsychological assessments, PET with ¹⁸F-fluorodeoxyglucose (FDG), and amyloid-PET with ¹⁸F-florbetaben.

Results

Patients with ALS showed hypometabolism in the frontal area and hypermetabolism in the cerebellum compared to healthy controls. Four patients (22 %) displayed cognitive impairment and decreased metabolism in the frontal area extending bilaterally to the parietal regions, and increased metabolism in the posterior area of the cerebellum. In patients with no cognitive impairment, metabolism was lower in the left superior frontal gyrus and higher in the anterior and posterior lobes of the cerebellum. In the individual analysis, six patients (35 %) displayed more anterior involvement with hypometabolism affecting the superior frontal, medial, and inferior gyri; six patients (35 %) exhibited a more posterior pattern with hypometabolism in the precentral and postcentral gyri and in the superior and inferior parietal lobules; two patients (11 %) showed a mixed pattern; and three patients (17 %) showed no alterations in brain metabolism. Three (16 %) showed increased ¹⁸F-florbetaben uptake compared to controls.

Conclusions

We have identified two main patterns of brain metabolism with an association to cognitive status. Only a subgroup of patients showed an increased uptake of the amyloid tracer. Our results suggest that ALS is heterogeneous from a clinical, metabolic, and molecular standpoint.

Nur mit Berechtigung zugänglich

Maekawa S, Al-Sarraj S, Kibble M, Landau S, Parnavelas J, Cotter D, et al. Cortical selective vulnerability in motor neuron disease: a morphometric study. Brain. 2004;127:1237–51.CrossRefPubMed

Takeda T, Uchihara T, Arai N, Mizutani T, Iwata M. Progression of hippocampal degeneration in amyotrophic lateral sclerosis with or without memory impairment: distinction from Alzheimer disease. Acta Neuropathol. 2009;117:35–44.CrossRefPubMed

Wilson CM, Grace GM, Munoz DG, He BP, Strong MJ. Cognitive impairment in sporadic ALS: a pathologic continuum underlying a multisystem disorder. Neurology. 2001;57:651–7.CrossRefPubMed

Coan G, Mitchell CS. An assessment of possible neuropathology and clinical relationships in 46 sporadic amyotrophic lateral sclerosis patient autopsies. Neurodegener Dis. 2015;15:301–12.CrossRefPubMedPubMedCentral

Machts J, Loewe K, Kaufmann J, Jakubiczka S, Abdulla S, Petri S, et al. Basal ganglia pathology in ALS is associated with neuropsychological deficits. Neurology. 2015;85:1301–9.CrossRefPubMed

Ludolph AC, Langen KJ, Regard M, Herzog H, Kemper B, Kuwert T, et al. Frontal lobe function in amyotrophic lateral sclerosis: a neuropsychologic and positron emission tomography study. Acta Neurol Scand. 1992;85:81–9.CrossRefPubMed

Abrahams S, Goldstein LH, Kew JJ, Brooks DJ, Lloyd CM, Frith CD, et al. Frontal lobe dysfunction in amyotrophic lateral sclerosis. A PET study. Brain. 1996;119:2105–20.CrossRefPubMed

Jeong Y, Park KC, Cho SS, Kim EJ, Kang SJ, Kim SE, et al. Pattern of glucose hypometabolism in frontotemporal dementia with motor neuron disease. Neurology. 2005;64:734–6.CrossRefPubMed

Renard D, Collombier L, Castelnovo G, Fourcade G, Kotzki PO, LaBauge P. Brain FDG-PET changes in ALS and ALS-FTD. Acta Neurol Belg. 2011;111:306–9.PubMed

10.

Pagani M, Chio A, Valentini MC, Oberg J, Nobili F, Calvo A, et al. Functional pattern of brain FDG-PET in amyotrophic lateral sclerosis. Neurology. 2014;83:1067–74.CrossRefPubMed

11.

Canosa A, Pagani M, Cistaro A, Montuschi A, Iazzolino B, Fania P, et al. 18F-FDG-PET correlates of cognitive impairment in ALS. Neurology. 2016;86:44–9.CrossRefPubMed

12.

Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351:602–11.CrossRefPubMed

13.

Kwong LK, Neumann M, Sampathu DM, Lee VM, Trojanowski JQ. TDP-43 proteinopathy: the neuropathology underlying major forms of sporadic and familial frontotemporal lobar degeneration and motor neuron disease. Acta Neuropathol. 2007;114(1):63–70.CrossRefPubMed

14.

Neumann M, Kwong LK, Sampathu DM, Trojanowski JQ, Lee VM. TDP-43 proteinopathy in frontotemporal lobar degeneration and amyotrophic lateral sclerosis: protein misfolding diseases without amyloidosis. Arch Neurol. 2007;64:1388–94.CrossRefPubMed

15.

Hamilton RL, Bowser R. Alzheimer disease pathology in amyotrophic lateral sclerosis. Acta Neuropathol. 2004;107:515–22.CrossRefPubMed

16.

Bryson JB, Hobbs C, Parsons MJ, Bosch KD, Pandraud A, Walsh FS, et al. Amyloid precursor protein (APP) contributes to pathology in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Hum Mol Genet. 2012;21:3871–82.CrossRefPubMed

17.

Edbauer D, Haass C. An amyloid-like cascade hypothesis for C9orf72 ALS/FTD. Curr Opin Neurobiol. 2016;36:99–106.CrossRefPubMed

18.

Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol. 2012;11:669–78.CrossRefPubMed

19.

Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer’s disease: phase 3 study. Alzheimers Dement. 2015;11:964–74.CrossRefPubMed

20.

Yamakawa Y, Shimada H, Ataka S, Tamura A, Masaki H, Naka H, et al. Two cases of dementias with motor neuron disease evaluated by Pittsburgh compound B-positron emission tomography. Neurol Sci. 2012;33:87–92.CrossRefPubMed

21.

Martikainen MH, Gardberg M, Jansson L, Roytta M, Rinne JO, Kaasinen V. Brain 18F-FDG and 11C-PiB PET findings in two siblings with FTD/ALS associated with the C9ORF72 repeat expansion. Neurocase. 2014;20:150–7.CrossRefPubMed

22.

Farid K, Carter SF, Rodriguez-Vieitez E, Almkvist O, Andersen P, Wall A, et al. Case report of complex amyotrophic lateral sclerosis with cognitive impairment and cortical amyloid deposition. J Alzheimers Dis. 2015;47:661–7.CrossRefPubMed

23.

Brooks BR, Miller RG, Swash M, Munsat TL. World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293–9.CrossRefPubMed

24.

Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98.CrossRef

25.

Matias-Guiu JA, de Bobadilla FR, Escudero G, Perez-Perez J, Cortes A, Morenas-Rodriguez E, et al. Validation of the Spanish version of Addenbrooke’s Cognitive Examination III for diagnosing dementia. Neurologia. 2015;30:545–51.CrossRefPubMed

26.

Kaplan E, Fein D, Morris R, Delis D. WAIS-R as a neuropsychological instrument. San Antonio: The Psychological Corporation; 1991.

27.

Partington J, Leiter R. Partington’s pathways test. Psychol Serv Cent Bull. 1949;1:9–20.

28.

Reitan RM, Wolfson D. The Halstead-Reitan neuropsychological test battery. Theory and clinical interpretation. 2nd ed. Tucson: Neuropsychology Press; 1993.

29.

Rey A. L’examen psychologique dans les cas d’encéphalopathie traumatique. Arch Psychol. 1941;28:215–85.

30.

Osterrieth PA. Le test de copie d’une figure complexe: contribution à l’etude de la perception et de la mémoire. Arch Psychol. 1944;30:206–356.

31.

Buschke H. Selective reminding for analysis of memory and learning. J Verbal Learn Verbal Behav. 1973;12:543–50.CrossRef

32.

Buschke H. Cued recall in amnesia. J Clin Neuropsychol. 1984;6:433–40.CrossRefPubMed

33.

Warrington EK, James M. Visual object and space perception battery. Suffolk: Thames Valley Test Company; 1991.

34.

Stroop JR. Studies of interference in serial verbal reaction. J Exp Psychol. 1935;18:643–62.CrossRef

35.

Golden CJ. Stroop color and word test. Chicago: Stoelting; 1978.

36.

Ramier AM, Hecaen H. Rôle respectif des atteintes frontales et de la latéralisation lésionnelle dans les déficits de la “fluence verbale”. Rev Neurol. 1970;123:17–22.PubMed

37.

Crawford JR, Wright R, Bate A. Verbal, figural and ideational fluency in CHI. International Neuropsychological Society and Australian Society for the Study of Brain Impairment, 2nd Pacific Rim Conference. Cairns: Australia. 1995;1:321.

38.

Culbertson WC, Zillmer EA. Tower of London: Drexel University (TOL DX). North Tonawanda: Multi-Health Systems; 2001.

39.

Pena-Casanova J, Blesa R, Aguilar M, Gramunt-Fombuena N, Gomez-Anson B, Oliva R, et al. Spanish multicenter normative studies (NEURONORMA Project): methods and sample characteristics. Arch Clin Neuropsychol. 2009;24:307–19.CrossRefPubMed

40.

Burgess PW, Alderman N, Evans J, Emslie H, Wilson B. The ecological validity of tests of executive function. J Int Neuropsychol Soc. 1998;4:547–58.CrossRefPubMed

41.

Piatt AL, Fields JA, Paolo AM, Troster AI. Action (verb naming) fluency as an executive function measure: convergent and divergent evidence of validity. Neuropsychologia. 1999;37:1499–503.CrossRefPubMed

42.

Burgess PW, Shallice T. The Hayling and Brixton Tests. Thames Valley Test Company: Thurston; 1997.

43.

Niven E, Newton J, Foley J, Colville S, Swingler R, Chandran S, et al. Validation of the Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen (ECAS): a cognitive tool for motor disorders. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:172–9.CrossRefPubMed

44.

Wear HJ, Wedderburn CJ, Mioshi E, Williams-Gray CH, Mason SL, Baker RA, et al. The Cambridge behavioural inventory revised. Dement Neuropsychol. 2008;2:102–7.

45.

Migliorelli R, Teson A, Sabe L, Petracca G, Petracchi M, Leiguarda R, et al. Anosognosia in Alzheimer’s disease: a study of associated factors. J Neuropsychiatry Clin Neurosci. 1995;7:338–44.CrossRefPubMed

46.

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (Revised 4th ed.). Washington, DC; 2000.

47.

Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999;169:13–21.CrossRefPubMed

48.

Della Rosa PA, Cerami C, Gallivanone F, Prestia A, Caroli A, Castiglioni I, et al. A standardized [18F]-FDG-PET template for spatial normalization in statistical parametric mapping of dementia. Neuroinformatics. 2014;12:575–93.CrossRefPubMed

49.

Matias-Guiu JA, Cabrera-Martin MN, Perez-Castejon MJ, Moreno-Ramos T, Rodriguez-Rey C, Garcia-Ramos R, et al. Visual and statistical analysis of 18F-FDG PET in primary progressive aphasia. Eur J Nucl Med Mol Imaging. 2015;42:916–27.CrossRefPubMed

50.

Lacadie CM, Fulbright RK, Todd Constable R, Papademetris X. More accurate Talairach coordinates for neuroimaging using nonlinear registration. Neuroimage. 2008;42:717–25.CrossRefPubMedPubMedCentral

51.

Tzourio-Mazoyer N, Landeau D, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15:273–89.CrossRefPubMed

52.

Fleisher AS, Chen K, Liu X, Roontiva A, Thiyyagura P, Ayutyanont N, et al. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol. 2011;68:1404–11.CrossRefPubMed

53.

IBM Corp. Released 2010. IBM SPSS Statistics for Mac, Version 19.0. Armonk, NY: IBM Corp.

54.

Montuschi A, Iazzolino B, Calvo A, Moglia C, Lopiano L, Restagno G, et al. Cognitive correlates in amyotrophic lateral sclerosis: a population-based study in Italy. J Neurol Neurosurg Psychiatry. 2015;86:168–73.CrossRefPubMed

55.

Sabatelli M, Conte A, Zollino M. Clinical and genetic heterogeneity of amyotrophic lateral sclerosis. Clin Genet. 2013;83:408–16.CrossRefPubMed

56.

Cistaro A, Pagani M, Montuschi A, Calvo A, Moglia C, Canosa A, et al. The metabolic signature of C9ORF72-related ALS: FDG PET comparison with nonmutated patients. Eur J Nucl Med Mol Imaging. 2014;41:844–52.CrossRefPubMed

57.

Whitwell JL, Weigand SD, Boeve BF, Senjem ML, Gunter JL, DeJesus-Hernandez M, et al. Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. Brain. 2012;135:794–806.CrossRefPubMedPubMedCentral

58.

Matias-Guiu JA, Cabrera-Martin MN, Moreno-Ramos T, Garcia-Ramos R, Porta-Etessam J, Carreras JL, et al. Clinical course of primary progressive aphasia: clinical and FDG-PET patterns. J Neurol. 2015;262:570–7.CrossRefPubMed

59.

Cistaro A, Valentini MC, Chio A, Nobili F, Calvo A, Moglia C, et al. Brain hypermetabolism in amyotrophic lateral sclerosis: a FDG PET study in ALS of spinal and bulbar onset. Eur J Nucl Med Mol Imaging. 2012;39:251–9.CrossRefPubMed

60.

Salmi J, Pallesen KJ, Neuvonen T, Brattico E, Korvenoja A, Salonen O, et al. Cognitive and motor loops of the human cerebro-cerebellar system. J Cogn Neurosci. 2010;22:2663–76.CrossRefPubMed

61.

O’Reilly JX, Beckmann CF, Tomassini V, Ramnani N, Johansen-Berg H. Distinct and overlapping functional zones in the cerebellum defined by resting state functional connectivity. Cereb Cortex. 2010;20:953–65.CrossRefPubMed

62.

Riedel MC, Ray KL, Dick AS, Sutherland MT, Hernandez Z, Fox PM, et al. Meta-analytic connectivity and behavioral parcellation of the human cerebellum. Neuroimage. 2015;117:327–42.CrossRefPubMedPubMedCentral

63.

Stoodley CJ, Valera EM, Schmahmann JD. Functional topography of the cerebellum for motor and cognitive tasks: an fMRI study. Neuroimage. 2012;59:1560–70.CrossRefPubMed

64.

Jack Jr CR, Wiste HJ, Weigand SD, Rocca WA, Knopman DS, Mielke MM, et al. Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50–89 years: a cross-sectional study. Lancet Neurol. 2014;13:997–1005.CrossRefPubMedPubMedCentral

65.

Skaper SD. Alzheimer’s disease and amyloid: culprit or coincidence? Int Rev Neurobiol. 2012;102:277–316.CrossRefPubMed

66.

Matias-Guiu JA, Cabrera-Martin MN, Matias-Guiu J, Oreja-Guevara C, Riola-Parada C, Moreno-Ramos T, et al. Amyloid PET imaging in multiple sclerosis: an (18)F-florbetaben study. BMC Neurol. 2015;15:243.CrossRefPubMedPubMedCentral

67.

Kuang G, Murugan N, Tu Y, Nordberg A, Agren H. Investigation of the binding profiles of AZD2184 and thioflavin T with amyloid-β(1–42) fibril by molecular docking and molecular dynamics methods. J Phys Chem B. 2015;119:11560–7.CrossRefPubMed

68.

Dukart J, Perneczky R, Forster S, Barthel H, Diehl-Schmid J, Draganski B, et al. Reference cluster normalization improves detection of frontotemporal lobar degeneration by means of FDG-PET. PLoS ONE. 2013;8, e5541.CrossRef

Titel: Amyloid- and FDG-PET imaging in amyotrophic lateral sclerosis
verfasst von: Jordi A. Matías-Guiu
Vanesa Pytel
María Nieves Cabrera-Martín
Lucía Galán
María Valles-Salgado
Antonio Guerrero
Teresa Moreno-Ramos
Jorge Matías-Guiu
José Luis Carreras
Publikationsdatum: 04.06.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 11/2016
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-016-3434-1

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2016

Biodistribution and radiation dosimetry of 68Ga-PSMA HBED CC—a PSMA specific probe for PET imaging of prostate cancer

18F-fluorocholine versus 18F-fluorodeoxyglucose for PET/CT imaging in patients with suspected relapsing or progressive multiple myeloma: a pilot study

A PET/CT approach to spinal cord metabolism in amyotrophic lateral sclerosis

Prognostic impact of incomplete surgical clearance of radioiodine sensitive local lymph node metastases diagnosed by post-operative 124I-NaI-PET/CT in patients with papillary thyroid cancer

Current knowledge on the sensitivity of the 68Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumours

Recommended administered activities for 68Ga-labelled peptides in paediatric nuclear medicine